Target intelligence / Profile preview

Crimean-Congo hemorrhagic fever virus glycoprotein (CCHFV glycoprotein)

Target
CCHFV glycoprotein
Molecular classification
Viral envelope glycoprotein, Class II membrane fusion protein (for Gc), Viral receptor-binding protein
01

Overview

The Crimean-Congo hemorrhagic fever virus glycoproteins (Gn, Gc, and GP38) are structural proteins located on the surface of the viral envelope, essential for the virus's ability to bind to host cell receptors, mediate membrane fusion, and initiate infection. Gn and Gc form heterodimers that create a lattice on the virion surface, orchestrating receptor-mediated endocytosis and driving membrane fusion via structural rearrangements, especially by Gc (a class II fusion protein). GP38 is a secreted glycoprotein unique to CCHFV, structurally related to Gn, and is the target of protective antibodies that can prevent infection in animal models, making it a promising candidate for vaccine or immunotherapeutic development. These glycoproteins are critical therapeutic targets due to their central role in viral entry and pathogenesis, but host protein-glycoprotein interactions remain incompletely characterized, complicating therapeutic strategies.

Other names
CCHFV glycoproteinCrimean-Congo hemorrhagic fever virus GnCrimean-Congo hemorrhagic fever virus GcCCHFV GP38
02

Mechanism of action

Neutralizing antibodies (e.g., targeting GP38 or Gc) inhibit viral attachment, membrane fusion, and entry into host cells Antibody-mediated immune clearance

03

Biological functions

Viral entry into host cells (mediated by Gn and Gc, receptor binding and membrane fusion)Interaction with multiple host cell proteins (implicated in modulation of cellular functions)Induction of immune responses (antibody targets, including neutralizing antibodies)Viral assembly and progeny virion packaging
04

Disease associations

Infection (agent of Crimean-Congo hemorrhagic fever)Antigenic determinant for immune response
05

Safety considerations

High containment required (biosafety level 4 pathogen)Antigenic variability may challenge vaccine or therapeutic efficacyNo licensed vaccines or specific antivirals currently available for human use
06

Interacting drugs

No approved drugs directly targeting CCHFV glycoproteins as of current data; however, monoclonal antibodies such as the GP38-targeting antibody 13G8 have shown protective activity in animal models
07

Biomarkers

Presence of antibodies against GP38 or Gc in sera may indicate prior infection or immunogenicity after vaccination

Beyond the preview

Go deeper on Crimean-Congo hemorrhagic fever virus glycoprotein (CCHFV glycoprotein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crimean-Congo hemorrhagic fever virus glycoprotein (CCHFV glycoprotein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call